pyrroles has been researched along with Retroperitoneal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, AM; Meric-Bernstam, F; Mills, GB; Pagliaro, LC; Rao, P; Shaw, KR; Subbiah, V; Ward, JF | 1 |
| Hohenberger, P; Jakob, J; Kasper, B; Ronellenfitsch, U; Simeonova, A; Wenz, F | 1 |
| Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ | 1 |
2 trial(s) available for pyrroles and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Platinum Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; Retroperitoneal Neoplasms; Sunitinib; Testicular Neoplasms; Young Adult | 2014 |
Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Retroperitoneal Neoplasms; Sarcoma; Sunitinib | 2015 |
1 other study(ies) available for pyrroles and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endpoint Determination; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Retroperitoneal Neoplasms; Retrospective Studies; Sunitinib; Suramin; Testicular Neoplasms; Topotecan; Treatment Outcome; Young Adult | 2012 |